Alastair Carruthers
Alastair Carruthers was a dermatologist whose work with ophthalmologist Jean Carruthers helped establish the clinical and professional pathway for cosmetic botulinum toxin use in glabellar frown lines.
In the Botulinum Index graph, he is a foundational aesthetic-medicine node: not the originator of therapeutic Botox, but one of the key figures connecting clinical observation, dermatology practice, and the later Botox Cosmetic market.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Professional field | Dermatology |
| Historical graph role | Aesthetic botulinum toxin adoption and clinical-publication node |
| Closely connected person | Jean Carruthers |
| Relevant brand node | Botox / Botox Cosmetic |
| Relevant company node | AbbVie / Allergan |
| Regulatory anchor | FDA approval of Botox Cosmetic for glabellar lines on April 12, 2002 |
Career Notes
Section titled “Career Notes”- Carruthers specialized in dermatology and became closely associated with cosmetic botulinum toxin use.
- With Jean Carruthers, he published the 1992 glabellar frown-lines paper that became a landmark in Botox Cosmetic’s aesthetic-use history.
- The American Society for Dermatologic Surgery context reported in 2024 described him as a pioneering dermatologic-surgery figure and noted his ASDS presidency from 2006 to 2007.
- He died on August 19, 2024, according to reporting based on the ASDS statement.
Why Alastair Carruthers Matters
Section titled “Why Alastair Carruthers Matters”Alastair Carruthers matters because the Botox Cosmetic story needed more than an observed wrinkle effect. It needed a dermatology pathway: defined treatment targets, professional presentation, published clinical experience, and a bridge from medical toxin use into aesthetic practice.
That makes him a different kind of person node from Alan B. Scott. Scott explains how botulinum toxin type A became a therapeutic product lineage. Alastair and Jean Carruthers explain how one visible facial indication became a major aesthetic-market anchor.
The distinction protects the graph from overclaiming. Alastair Carruthers did not make all toxin products comparable, and the cosmetic success of Botox Cosmetic does not create unit equivalence or shared indications across brands.
Botox Cosmetic Context
Section titled “Botox Cosmetic Context”The Carruthers contribution connects most directly to glabellar lines, the vertical frown-line area between the eyebrows. FDA’s 2002 approval letter allowed Botulinum Toxin Type A to be marketed and labeled as Botox Cosmetic for temporary improvement in moderate to severe glabellar lines under the approval’s adult-patient language.
That approval is the regulatory turning point. The Carruthers work is the clinical-history path that helps explain why the approval mattered to aesthetic medicine and the wider botulinum toxin market.
Activity and Public Context
Section titled “Activity and Public Context”Later media and professional-society accounts often describe Alastair Carruthers as a pioneer of cosmetic Botox. For this index, the most useful formulation is narrower and more durable: he is a key dermatologist in the glabellar-line aesthetic-use pathway that helped make Botox Cosmetic a distinct market and label identity.
For product interpretation, readers should move from Carruthers to Botox and current label sources. For the therapeutic origin of the Botox franchise, readers should move to Alan B. Scott.